Search

Your search keyword '"Tije, Bert-Jan J Ten"' showing total 7 results
Start Over Author "Tije, Bert-Jan J Ten"
7 results on '"Tije, Bert-Jan J Ten"'

1. First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Author

van Breeschoten, Jesper, Wouters, Michel W. J. M., Hilarius, Doranne L., Haanen, John B., Blank, Christian U., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., de Groot, Jan-Willem B., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S., Suijkerbuijk, Karijn P. M., Blokx, Willeke A. M., Tije, Bert-Jan J. ten, Veldt, Astrid A. M. van der, Vreugdenhil, Art, Boers-Sonderen, Marye J., and van den Eertwegh, Alfonsus J. M.

Published
2021
Full Text
View/download PDF

2. Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Author

van Breeschoten, Jesper, Wouters, Michel W. J. M., Hilarius, Doranne L., Haanen, John B., Blank, Christian U., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., de Groot, Jan-Willem B., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S., Suijkerbuijk, Karijn P. M., Blokx, Willeke A. M., Tije, Bert-Jan J. ten, Veldt, Astrid A. M. van der, Vreugdenhil, Art, Boers-Sonderen, Marye J., and van den Eertwegh, Alfonsus J. M.

Published
2022
Full Text
View/download PDF

3. Correction:First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 124, 7, (1222-1230), 10.1038/s41416-020-01229-1)

Author

van Breeschoten, Jesper, Wouters, Michel W. J. M., Hilarius, Doranne L., Haanen, John B., Blank, Christian U., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., de Groot, Jan-Willem B., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S., Suijkerbuijk, Karijn P. M., Blokx, Willeke A. M., Tije, Bert-Jan J. ten, Veldt, Astrid A. M. van der, Vreugdenhil, Art, Boers-Sonderen, Marye J., van den Eertwegh, Alfonsus J. M., Internal medicine, Obstetrics and gynaecology, Amsterdam Reproduction & Development (AR&D), Medical oncology, AII - Cancer immunology, CCA - Cancer biology and immunology, and CCA - Cancer Treatment and quality of life

Abstract

The original version of this article unfortunately contained a mistake. During online publication of this article an incorrect notification was included by the Publisher in the Additional Information. The notification incorrectly stated that the licence terms for these articles would switch to a Creative Commons Attribution 4.0 International (CC BY 4.0) after a period of 12 months. This notification has been removed and the articles have been updated.

Published
2022
Full Text
View/download PDF

4. First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis

Author

MS Medische Oncologie, Infection & Immunity, Cancer, Pathologie Pathologen staf, van Breeschoten, Jesper, Wouters, Michel W J M, Hilarius, Doranne L, Haanen, John B, Blank, Christian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, de Groot, Jan-Willem B, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S, Suijkerbuijk, Karijn P M, Blokx, Willeke A M, Tije, Bert-Jan J Ten, Veldt, Astrid A M van der, Vreugdenhil, Art, Boers-Sonderen, Marye J, van den Eertwegh, Alfonsus J M, MS Medische Oncologie, Infection & Immunity, Cancer, Pathologie Pathologen staf, van Breeschoten, Jesper, Wouters, Michel W J M, Hilarius, Doranne L, Haanen, John B, Blank, Christian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, de Groot, Jan-Willem B, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S, Suijkerbuijk, Karijn P M, Blokx, Willeke A M, Tije, Bert-Jan J Ten, Veldt, Astrid A M van der, Vreugdenhil, Art, Boers-Sonderen, Marye J, and van den Eertwegh, Alfonsus J M

Published
2022

5. First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Author

MS Medische Oncologie, Infection & Immunity, Cancer, Pathologie Pathologen staf, van Breeschoten, Jesper, Wouters, Michel W J M, Hilarius, Doranne L, Haanen, John B, Blank, Christian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, de Groot, Jan-Willem B, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S, Suijkerbuijk, Karijn P M, Blokx, Willeke A M, Tije, Bert-Jan J Ten, Veldt, Astrid A M van der, Vreugdenhil, Art, Boers-Sonderen, Marye J, van den Eertwegh, Alfonsus J M, MS Medische Oncologie, Infection & Immunity, Cancer, Pathologie Pathologen staf, van Breeschoten, Jesper, Wouters, Michel W J M, Hilarius, Doranne L, Haanen, John B, Blank, Christian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, de Groot, Jan-Willem B, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S, Suijkerbuijk, Karijn P M, Blokx, Willeke A M, Tije, Bert-Jan J Ten, Veldt, Astrid A M van der, Vreugdenhil, Art, Boers-Sonderen, Marye J, and van den Eertwegh, Alfonsus J M

Published
2021

6. First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis.

Author

van Breeschoten, Jesper, Wouters, Michel W. J. M., Hilarius, Doranne L., Haanen, John B., Blank, Christian U., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., de Groot, Jan-Willem B., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S., Suijkerbuijk, Karijn P. M., Blokx, Willeke A. M., Tije, Bert-Jan J. ten, Veldt, Astrid A. M. van der, Vreugdenhil, Art, Boers-Sonderen, Marye J., and van den Eertwegh, Alfonsus J. M.

Abstract

Background: Anti-PD-1 antibodies and BRAF/MEK inhibitors are the two main groups of systemic therapy in the treatment of BRAFV600-mutant advanced melanoma. Until now, data are inconclusive on which therapy to use as first-line treatment. The aim of this study was to use propensity score matching to compare first-line anti-PD-1 monotherapy vs. BRAF/MEK inhibitors in advanced BRAFV600-mutant melanoma patients.Methods: We selected patients diagnosed between 2014 and 2017 with advanced melanoma and a known BRAFV600-mutation treated with first-line BRAF/MEK inhibitors or anti-PD-1 antibodies, registered in the Dutch Melanoma Treatment Registry. Patients were matched based on their propensity scores using the nearest neighbour and the optimal matching method.Results: Between 2014 and 2017, a total of 330 and 254 advanced melanoma patients received BRAF/MEK inhibitors and anti-PD-1 monotherapy as first-line systemic therapy. In the matched cohort, patients receiving anti-PD-1 antibodies as a first-line treatment had a higher median and 2-year overall survival compared to patients treated with first-line BRAF/MEK inhibitors, 42.3 months (95% CI: 37.3-NE) vs. 19.8 months (95% CI: 16.7-24.3) and 65.4% (95% CI: 58.1-73.6) vs. 41.7% (95% CI: 34.2-51.0).Conclusions: Our data suggest that in the matched BRAFV600-mutant advanced melanoma patients, anti-PD-1 monotherapy is the preferred first-line treatment in patients with relatively favourable patient and tumour characteristics. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

7. Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis.

Author

van Breeschoten, Jesper, Wouters, Michel W. J. M., Hilarius, Doranne L., Haanen, John B., Blank, Christian U., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., de Groot, Jan-Willem B., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S., Suijkerbuijk, Karijn P. M., Blokx, Willeke A. M., Tije, Bert-Jan J. ten, Veldt, Astrid A. M. van der, Vreugdenhil, Art, Boers-Sonderen, Marye J., and van den Eertwegh, Alfonsus J. M.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results